Intellia Therapeutics
Develops CRISPR medicines led by lonvo-z and nex-z.
$12.87
After-hours close−0.00 (−0.01%)
At close$12.88(−1.79%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 105.68%Insiders 1.73%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 139.72M · Float 133.81M · 95.8% free float
Institutions13F, as of Jun 30, 2026
353 holders · 147.65M shares · 57 new positions · 197 increased · 81 reduced · 31 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Ark Investment Management LLC | 16.88M | 12.08% | +2.37M | Aug 14, 2026 |
| BlackRock, Inc. | 15.41M | 11.03% | +3.25M | Aug 7, 2026 |
| State Street Corp | 9.23M | 6.61% | +2.31M | Aug 7, 2026 |
| Vanguard Portfolio Management LLC | 7.33M | 5.25% | +1.11M | Aug 13, 2026 |
| D. E. Shaw & Co., Inc. | 6.44M | 4.61% | +715.1K | Aug 14, 2026 |
| Vanguard Capital Management LLC | 6.03M | 4.31% | +944.5K | Aug 13, 2026 |
| Two Sigma Investments, LP | 5.24M | 3.75% | +529.4K | Aug 14, 2026 |
| FMR LLC | 4.77M | 3.42% | +2.71M | Aug 13, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| ARK Investment Management LLC | 12.27% | 14.21M | 13G | Feb 3, 2026 ↗ |
| BlackRock, Inc. | 8.20% | 8.45M | 13G | Apr 17, 2025 ↗ |
| State Street Corporation | 6.80% | 9.23M | 13G | Aug 7, 2026 ↗ |
| Vanguard Portfolio Management | 5.30% | 6.27M | 13G | Apr 29, 2026 ↗ |
| Vanguard Capital Management | 5.03% | 5.95M | 13G | Apr 30, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| John M. Leonard | director, officer: President and CEO | 1.15M | 0.82% | Aug 24, 2026 |
| Fred E. Cohen | director | 216.7K | 0.16% | Jun 10, 2026 |
| James Basta | officer: EVP, General Counsel | 156.8K | 0.11% | Mar 3, 2026 |
| Edward J. III Dulac | officer: EVP, Chief Financial Officer | 148.2K | 0.11% | Jul 24, 2026 |
| William J. Chase | director | 143.9K | 0.10% | Jun 10, 2026 |
| Birgit C. Schultes | officer: EVP, Chief Scientific Officer | 137.7K | 0.10% | Mar 3, 2026 |
| David Lebwohl | officer: EVP, Chief Medical Officer | 131.2K | 0.09% | Mar 3, 2026 |
| Eliana Clark | officer: EVP, Chief Technical Officer | 93.9K | 0.07% | Mar 3, 2026 |
| Michael P. Dube | officer: VP, Chief Accounting Officer | 66.9K | 0.05% | Jul 6, 2026 |
| Georgia Keresty | director | 41.1K | 0.03% | Jun 10, 2026 |
6 ten-percent owners hold 12.76M shares by Form 4, outside the officers-and-directors figure above · 18 people have not refiled in the last 18 months (5.48M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 21, 2026 | John M. Leonarddirector, officer: President and CEO | Sale | 2,785 | $13.00 | 1,147,064 |
| Aug 20, 2026 | John M. Leonarddirector, officer: President and CEO | Sale | 19,890 | $12.60 | 1,149,849 |
| Jul 22, 2026 | Edward J. III Dulacofficer: EVP, Chief Financial Officer | Sale | 8,111 | $11.25 | 148,175 |
| Jul 2, 2026 | Edward J. III Dulacofficer: EVP, Chief Financial Officer | Sale | 4,677 | $18.00 | 156,286 |
| Jul 1, 2026 | Michael P. Dubeofficer: VP, Chief Accounting Officer | Sale | 2,641 | $16.78 | 66,886 |
| Mar 2, 2026 | Eliana Clarkofficer: EVP, Chief Technical Officer | Sale | 607 | $13.78 | 93,864 |
| Mar 2, 2026 | James Bastaofficer: EVP, General Counsel | Sale | 1,211 | $13.78 | 156,794 |
| Jan 5, 2026 | Michael P. Dubeofficer: VP, Chief Accounting Officer | Sale | 2,989 | $9.21 | 52,277 |
| Jan 5, 2026 | Edward J. III Dulacofficer: EVP, Chief Financial Officer | Sale | 6,379 | $9.21 | 99,683 |
| Jan 5, 2026 | Eliana Clarkofficer: EVP, Chief Technical Officer | Sale | 9,515 | $9.21 | 87,118 |
CongressHouse and Senate disclosures
Not reported.